ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression
Journal of Clinical Investigation · 17.08.2026 · 136 (16)
DOI: 10.1172/jci192285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 07.07.2026. Verfasst von Xinyi Tu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Ataxia Telangiectasia Mutated Proteins, Extracellular Matrix, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NCI NIH HHS, Mayo Clinic Research Pipeline K2R Award.
Abstract (Originalsprache)
Our research uncovers a role for ATR in responding to ECM stiffness and promoting epithelial-to-mesenchymal transition (EMT) and metastasis. ATR, when deubiquitinated and upregulated by USP21 under enhanced ECM stiffness conditions, phosphorylates the nuclear protein SUN2, which promotes β-catenin nuclear translocation and EMT. ATM-mediated EMT promotes polymorphonuclear myeloid-derived suppressor cell recruitment and inhibits CD103 + dendritic cells, fostering an immunosuppressive tumor milieu. ATR inhibition disrupts this malignant cascade by promoting mesenchymal-to-epithelial transition to enhance antitumor immunity and mitigate metastases. Consistently, circulating HLA-DR + dendritic cells were also enhanced following treatment with the ATR inhibitor berzosertib in patients with therapeutically resistant early-stage breast cancer. Our data suggest that ATR-targeted therapy may be optimized by considering both DNA damage–dependent and EMT-inducing effects of ATR ATR promotes metastasis and immunosuppression through EMT process
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology.
- Molecular Pharmacology and Experimental Therapeutics.
- Department of Immunology.
- Department of Oncology.
- Department of Medical Oncology, and.
- Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.
Förderung
- NICHD NIH HHS
- NCI NIH HHS
- Mayo Clinic Research Pipeline K2R Award
- National Cancer Center
- Mayo Clinic Breast Caner SPORE pilot project
- Eagle fellowship award
- Wallace and Evelyn Simmers Career Development Award
- Breast SPORE
Zitieren
APA
Tu, X., Zeng, X., Sun, Y., Ouyang, Y., Zhu, L., Yin, P., Pavelko, K., Leon-Ferre, R., Jiang, Y., Dong, H., Carter, J., Zhu, S., Sarkaria, J. N., Wang, L., Huang, J., Luo, K., Han, Y., Wu, Z., Lou, Z., & Mutter, R. W. (2026). ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression. Journal of Clinical Investigation, 136(16). https://doi.org/10.1172/jci192285
Vancouver
Tu X, Zeng X, Sun Y, Ouyang Y, Zhu L, Yin P, et al. ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression. Journal of Clinical Investigation. 2026;136(16). doi:10.1172/jci192285
BibTeX
@article{Tu2026,
author = {Tu, Xinyi and Zeng, Xiangyu and Sun, Yaoliang and Ouyang, Yaobin and Zhu, Lingling and Yin, Ping and Pavelko, Kevin and Leon-Ferre, Roberto and Jiang, Yanxia and Dong, Haidong and Carter, Jodi and Zhu, Shouhai and Sarkaria, Jann N and Wang, Liewei and Huang, Jinzhou and Luo, Kuntian and Han, Yiqun and Wu, Zheming and Lou, Zhenkun and Mutter, Robert W},
title = {ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {16},
doi = {10.1172/jci192285}
}
EUVIMED